Cargando…

Sophora flavescens Alkaloids and Corticosteroid Synergistically Augment IL-10/IL-5 Ratio with Foxp3-Gene-Epigenetic Modification in Asthma PBMCs

BACKGROUND: It has been demonstrated that ASHMI (antiasthma-simplified herbal medicine intervention) can improve airway function and reduce inflammation in human asthmatic patients with high safety and tolerability. In addition, ASHMI significantly suppresses Th2 cytokine production and increases Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Ying, Wang, Zhen-Zhen, Wang, Lixin, Faybusovich, Paul, Srivastava, Kamal, Liu, Changda, Tversky, Jody, Dunkin, David, Busse, Paula, Ren, Xianqing, Miller, Rachel, Miao, Mingsan, Li, Xiu-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711843/
https://www.ncbi.nlm.nih.gov/pubmed/34992384
http://dx.doi.org/10.2147/JAA.S321616
_version_ 1784623441920393216
author Song, Ying
Wang, Zhen-Zhen
Wang, Lixin
Faybusovich, Paul
Srivastava, Kamal
Liu, Changda
Tversky, Jody
Dunkin, David
Busse, Paula
Ren, Xianqing
Miller, Rachel
Miao, Mingsan
Li, Xiu-Min
author_facet Song, Ying
Wang, Zhen-Zhen
Wang, Lixin
Faybusovich, Paul
Srivastava, Kamal
Liu, Changda
Tversky, Jody
Dunkin, David
Busse, Paula
Ren, Xianqing
Miller, Rachel
Miao, Mingsan
Li, Xiu-Min
author_sort Song, Ying
collection PubMed
description BACKGROUND: It has been demonstrated that ASHMI (antiasthma-simplified herbal medicine intervention) can improve airway function and reduce inflammation in human asthmatic patients with high safety and tolerability. In addition, ASHMI significantly suppresses Th2 cytokine production and increases Th1 cytokine production in treating asthma. OBJECTIVE: Allergic asthma is associated with dysregulation of cytokines. We focused on IL-5 and IL-10 as signature Th2 and Treg cytokines to characterize ASHMI immunomodulatory components. METHODS: The effects of ASHMI and individual herbal constituents on IL-5 and IL-10 production by PBMCs from asthmatic subjects were determined ex vivo. Sophora flavescens (SF)-F2, containing alkaloid compounds, effects on PBMC IL-10 and IL-5 production in the presence or absence of dexamethasone (Dex), and on DNA methylation levels at the foxp3 gene promoter were determined. RESULTS: The ratio of anti-CD3/CD28 stimulated IL-10/IL-5 production by PBMCs from asthmatic subjects was significantly reduced compared to healthy subjects. In PBMCs from asthmatic subjects, ASHMI significantly reduced IL-5 production and increased IL-10 secretion in a dose-dependent manner (p < 0.05–0.01). SF-F2 was most effective in increasing IL-10, whereas SF-F4 (flavonoid compounds) was most effective in suppressing IL-5 production. Dex-treated PBMCs from asthma subjects showed a trend of increasing ratio of IL-10/IL-5 while demonstrating reduced levels in both IL-5 and IL-10 (p < 0.05). Co-culture with Dex and SF-F2 significantly prevented Dex suppression of IL-10, while retained Dex-suppression of IL-5 production, and increased IL-10/IL-5 ratio by Dex. Co-culture with SF-F2 and Dex significantly reduced DNA methylation levels at the foxp3 gene promoter at CpG(−126). CONCLUSION: The SF alkaloid-rich fraction may be responsible for ASHMI induction of IL-10 production by PBMCs and plays a synergistic effect with Dex for augmenting IL-10/IL-5 ratio.
format Online
Article
Text
id pubmed-8711843
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-87118432022-01-05 Sophora flavescens Alkaloids and Corticosteroid Synergistically Augment IL-10/IL-5 Ratio with Foxp3-Gene-Epigenetic Modification in Asthma PBMCs Song, Ying Wang, Zhen-Zhen Wang, Lixin Faybusovich, Paul Srivastava, Kamal Liu, Changda Tversky, Jody Dunkin, David Busse, Paula Ren, Xianqing Miller, Rachel Miao, Mingsan Li, Xiu-Min J Asthma Allergy Original Research BACKGROUND: It has been demonstrated that ASHMI (antiasthma-simplified herbal medicine intervention) can improve airway function and reduce inflammation in human asthmatic patients with high safety and tolerability. In addition, ASHMI significantly suppresses Th2 cytokine production and increases Th1 cytokine production in treating asthma. OBJECTIVE: Allergic asthma is associated with dysregulation of cytokines. We focused on IL-5 and IL-10 as signature Th2 and Treg cytokines to characterize ASHMI immunomodulatory components. METHODS: The effects of ASHMI and individual herbal constituents on IL-5 and IL-10 production by PBMCs from asthmatic subjects were determined ex vivo. Sophora flavescens (SF)-F2, containing alkaloid compounds, effects on PBMC IL-10 and IL-5 production in the presence or absence of dexamethasone (Dex), and on DNA methylation levels at the foxp3 gene promoter were determined. RESULTS: The ratio of anti-CD3/CD28 stimulated IL-10/IL-5 production by PBMCs from asthmatic subjects was significantly reduced compared to healthy subjects. In PBMCs from asthmatic subjects, ASHMI significantly reduced IL-5 production and increased IL-10 secretion in a dose-dependent manner (p < 0.05–0.01). SF-F2 was most effective in increasing IL-10, whereas SF-F4 (flavonoid compounds) was most effective in suppressing IL-5 production. Dex-treated PBMCs from asthma subjects showed a trend of increasing ratio of IL-10/IL-5 while demonstrating reduced levels in both IL-5 and IL-10 (p < 0.05). Co-culture with Dex and SF-F2 significantly prevented Dex suppression of IL-10, while retained Dex-suppression of IL-5 production, and increased IL-10/IL-5 ratio by Dex. Co-culture with SF-F2 and Dex significantly reduced DNA methylation levels at the foxp3 gene promoter at CpG(−126). CONCLUSION: The SF alkaloid-rich fraction may be responsible for ASHMI induction of IL-10 production by PBMCs and plays a synergistic effect with Dex for augmenting IL-10/IL-5 ratio. Dove 2021-12-23 /pmc/articles/PMC8711843/ /pubmed/34992384 http://dx.doi.org/10.2147/JAA.S321616 Text en © 2021 Song et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Song, Ying
Wang, Zhen-Zhen
Wang, Lixin
Faybusovich, Paul
Srivastava, Kamal
Liu, Changda
Tversky, Jody
Dunkin, David
Busse, Paula
Ren, Xianqing
Miller, Rachel
Miao, Mingsan
Li, Xiu-Min
Sophora flavescens Alkaloids and Corticosteroid Synergistically Augment IL-10/IL-5 Ratio with Foxp3-Gene-Epigenetic Modification in Asthma PBMCs
title Sophora flavescens Alkaloids and Corticosteroid Synergistically Augment IL-10/IL-5 Ratio with Foxp3-Gene-Epigenetic Modification in Asthma PBMCs
title_full Sophora flavescens Alkaloids and Corticosteroid Synergistically Augment IL-10/IL-5 Ratio with Foxp3-Gene-Epigenetic Modification in Asthma PBMCs
title_fullStr Sophora flavescens Alkaloids and Corticosteroid Synergistically Augment IL-10/IL-5 Ratio with Foxp3-Gene-Epigenetic Modification in Asthma PBMCs
title_full_unstemmed Sophora flavescens Alkaloids and Corticosteroid Synergistically Augment IL-10/IL-5 Ratio with Foxp3-Gene-Epigenetic Modification in Asthma PBMCs
title_short Sophora flavescens Alkaloids and Corticosteroid Synergistically Augment IL-10/IL-5 Ratio with Foxp3-Gene-Epigenetic Modification in Asthma PBMCs
title_sort sophora flavescens alkaloids and corticosteroid synergistically augment il-10/il-5 ratio with foxp3-gene-epigenetic modification in asthma pbmcs
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711843/
https://www.ncbi.nlm.nih.gov/pubmed/34992384
http://dx.doi.org/10.2147/JAA.S321616
work_keys_str_mv AT songying sophoraflavescensalkaloidsandcorticosteroidsynergisticallyaugmentil10il5ratiowithfoxp3geneepigeneticmodificationinasthmapbmcs
AT wangzhenzhen sophoraflavescensalkaloidsandcorticosteroidsynergisticallyaugmentil10il5ratiowithfoxp3geneepigeneticmodificationinasthmapbmcs
AT wanglixin sophoraflavescensalkaloidsandcorticosteroidsynergisticallyaugmentil10il5ratiowithfoxp3geneepigeneticmodificationinasthmapbmcs
AT faybusovichpaul sophoraflavescensalkaloidsandcorticosteroidsynergisticallyaugmentil10il5ratiowithfoxp3geneepigeneticmodificationinasthmapbmcs
AT srivastavakamal sophoraflavescensalkaloidsandcorticosteroidsynergisticallyaugmentil10il5ratiowithfoxp3geneepigeneticmodificationinasthmapbmcs
AT liuchangda sophoraflavescensalkaloidsandcorticosteroidsynergisticallyaugmentil10il5ratiowithfoxp3geneepigeneticmodificationinasthmapbmcs
AT tverskyjody sophoraflavescensalkaloidsandcorticosteroidsynergisticallyaugmentil10il5ratiowithfoxp3geneepigeneticmodificationinasthmapbmcs
AT dunkindavid sophoraflavescensalkaloidsandcorticosteroidsynergisticallyaugmentil10il5ratiowithfoxp3geneepigeneticmodificationinasthmapbmcs
AT bussepaula sophoraflavescensalkaloidsandcorticosteroidsynergisticallyaugmentil10il5ratiowithfoxp3geneepigeneticmodificationinasthmapbmcs
AT renxianqing sophoraflavescensalkaloidsandcorticosteroidsynergisticallyaugmentil10il5ratiowithfoxp3geneepigeneticmodificationinasthmapbmcs
AT millerrachel sophoraflavescensalkaloidsandcorticosteroidsynergisticallyaugmentil10il5ratiowithfoxp3geneepigeneticmodificationinasthmapbmcs
AT miaomingsan sophoraflavescensalkaloidsandcorticosteroidsynergisticallyaugmentil10il5ratiowithfoxp3geneepigeneticmodificationinasthmapbmcs
AT lixiumin sophoraflavescensalkaloidsandcorticosteroidsynergisticallyaugmentil10il5ratiowithfoxp3geneepigeneticmodificationinasthmapbmcs